Document:

Amendment No. 1 to Collaboration Agreement

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 Exhibit 10.1 
 AMENDMENT NO.1 TO COLLABORATION AGREEMENT 

This Amendment No. 1 to the Collaboration Agreement (this “Amendment”) is entered into and effective as of January 1, 2010 (the
“Amendment Effective Date”) by and among MEDIVATION, INC., a Delaware corporation having its principal place of business at 201 Spear Street, 3rd Floor, San Francisco, California 94105, United States, its wholly owned subsidiary Medivation
Prostate Therapeutics, Inc., a Delaware corporation having its principal place of business at the same location (such entities, collectively, “Medivation”), ASTELLAS PHARMA INC., a Japanese corporation having a principal office at 3-11,
Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“API”) and its indirect wholly owned subsidiary Astellas US LLC, a Delaware limited liability company having its principal place of business at Three Parkway North, Deerfield,
Illinois 60015, United States (“AUS”; collectively with API, “Astellas”). Medivation and Astellas are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 
 A. The
Parties entered into a certain Collaboration Agreement effective as of October 26, 2009 (the “Collaboration Agreement”). 
 B.
The Parties wish to amend the Collaboration Agreement. 
 NOW, THEREFORE, the Parties hereby agree to amend the Collaboration
Agreement as follows: 
 1. Unless otherwise expressly provided in this Amendment, all definitions in the Collaboration Agreement shall be also
applicable to this Amendment. 
 2. The third and forth sentences of Section 9.2 of the Collaboration Agreement shall be deleted and
replaced with the following: 
 “Within [ * ] Business Days after receipt of such reports, the Finance Officers shall confer and agree in
writing on whether a reconciliation payment is due from Medivation to AUS or AUS to Medivation, and if so, the amount of such reconciliation payment, so that Medivation and AUS share Joint Development Costs, Joint Medical Affairs Costs and Joint
Commercialization Costs in accordance with this Agreement. Medivation or AUS, as applicable, if required to pay such reconciliation payment, shall submit such payment to AUS or Medivation, respectively, as applicable, within [ * ] Business Days
after the end of such [ * ] Business Day conferral period; provided, however, that in the event of any disagreement with respect to the calculation of such reconciliation payment, any undisputed portion of such reconciliation payment shall be paid
in accordance with the foregoing timetable and the remaining, disputed portion shall be paid within [ * ] 

 
Business Days after the date on which Medivation and AUS, using good faith efforts, resolve the dispute.” 
 3. The third and forth sentences of Section 9.3(b) of the Collaboration Agreement shall be deleted and replaced with the following: 
 “Within [ * ] Business Days after receipt of such reports, the Finance Officers shall confer and agree upon in writing a consolidated financial statement setting forth the Operating Profit or
Operating Loss for such calendar quarter for such Product in the Shared Territory and calculating each Party’s share of such Operating Profit or Operating Loss. Within [ * ] Business Days after such [ * ] Business Day conferral period,
Medivation or AUS, as applicable, shall make a payment to AUS or Medivation respectively, as applicable, so that each of Medivation and AUS has been compensated for its respective share of such Operating Profits, or has borne its respective share of
such Operating Loss, as applicable, after giving effect to the Net Sales invoiced by AUS and the Joint Development Costs, Joint Medical Affairs Costs, and Joint Commercialization Costs incurred by Medivation and AUS with respect to such Product in
such calendar quarter; provided, however, that in the event of any disagreement with respect to the calculation of such payment, any undisputed portion of such payment shall be paid in accordance with the foregoing timetable and the remaining,
disputed portion shall be paid within [ * ] Business Days after the date on which Medivation and AUS, using good faith efforts, resolve the dispute.” 
 4. Except as specifically amended by this Amendment, the Collaboration Agreement remains in full force and effect. Wherever the terms of this Amendment and the Collaboration Agreement conflict, this
Amendment controls. All references in the Collaboration to “this Agreement” shall mean the Collaboration Agreement, as amended hereby. 
 5. This Amendment may be executed in counterparts, which together shall constitute one and the same instrument. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 IN WITNESS WHEREOF, the Parties have executed this
Agreement in duplicate originals by their duly authorized officers as of the Amendment Effective Date. 
  

			
	 MEDIVATION, INC.

 
 By: /s/ C. Patrick Machado

 
 Name: C. Patrick Machado

 
 Title: CFO and CBO
	  	 ASTELLAS PHARMA INC.

 
 By: /s/ Masafumi Nogimori

 
 Name: Masafumi Nogimori

 
 Title: President and CEO

		
	 MEDIVATION PROSTATE THERAPEUTICS, INC.

 
 By: /s/ C. Patrick Machado

 
 Name: C. Patrick Machado

 
 Title: CFO
	  	 ASTELLAS US LLC
  

By: /s/ Seigo Kashii
  
 Name: Seigo Kashii
  
 Title:
President and CEO

  
 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.Amendment No. 2 to Collaboration Agreement

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 Exhibit 10.2 
 AMENDMENT NO. 2 TO COLLABORATION AGREEMENT 

This Amendment No. 2 (this “Amendment”) is entered into this 13th day of May, 2011 (“Amendment Effective Date”), by
and among MEDIVATION, INC., a Delaware corporation having its principal place of business at 201 Spear Street, 3rd Floor, San Francisco, California 94105, United States, its wholly owned subsidiary MEDIVATION PROSTATE THERAPEUTICS, INC., a Delaware
corporation having its principal place of business at the same location (such entities, collectively, “Medivation”), ASTELLAS PHARMA INC., a Japanese corporation having its principal place of business at 3-11, Nihonbashi-Honcho
2-chome, Chuo-ku, Tokyo 103-8411, Japan (“API”) and its indirect wholly owned subsidiary Astellas US LLC, a Delaware limited liability company having its principal place of business at Three Parkway North, Deerfield, Illinois 60015,
United States (“AUS”; collectively with API, “Astellas”) and amends the Collaboration Agreement effective as of October 26, 2009 as previously amended (the “Collaboration Agreement”).
Medivation and Astellas are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. Unless otherwise expressly provided in this Amendment, all definitions in the Collaboration Agreement
shall be also applicable to this Amendment. All references to “Sections” “Articles” and “Exhibits” refer to sections, articles and exhibits of the Collaboration Agreement. 

RECITALS 

WHEREAS, in a meeting on March 4, 2010, in accordance with Section 2.3(b)(xii)(C), the JDC determined to recommend to the JSC as the second
pivotal Clinical Trial to be initiated under the Collaboration the protocol entitled “PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy Naïve Patients
with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy” (the Clinical Trial identified by such protocol shall be referred to as the “PREVAIL Trial”); and 

WHEREAS, on March 6, 2010, in accordance with Section 2.2(c)(iii), the JSC (by phone and e-mail) endorsed the PREVAIL Trial as the
second pivotal Clinical Trial to be initiated under the Collaboration; and 
 WHEREAS, on September 28, 2010, the first patient was
dosed in the PREVAIL Trial; and 
 WHEREAS, on October 27, 2010, Astellas [ * ] paid Medivation the sum of Ten Million Dollars
($10,000,000.00) [ * ], in accordance with Section 9.4(a); and 

  
 1 

 WHEREAS, the Parties have been in discussions regarding [ * ] with respect to whether the [ * ] has
been [ * ] to [ * ] of [ * ] for [ * ] and the [ * ], such that [ * ] should [ * ] under Section [ * ] with respect to the [ * ] in the [ * ] for the [ * ]; and 
 WHEREAS, the Parties wish to [ * ]. 
 NOW, THEREFORE, in consideration for the
foregoing premises and the mutual promises and covenants and conditions in this Amendment, the Parties hereby agree to amend the Collaboration Agreement as follows 
  

	1.	The [ * ] Milestone. 

1.1 Within [ * ] days of the Amendment Effective Date, Astellas shall pay Medivation the sum of Three Million Dollars
($3,000,000.00). Such payment shall [ * ] milestone payment that is due upon achievement of the [ * ] with respect to the [ * ] under Section 9.4(a) (the “[ * ] Milestone”). 

1.2 The [ * ] of the [ * ] Milestone shall be [ * ] payable within [ * ] of the earlier to occur of: (i) the first [ * ] for
a Product with a [ * ] the [ * ] obtained in [ * ], the [ * ] or [ * ]; or (ii) the first [ * ] in any [ * ] other than the [ * ] initiated under the Collaboration Agreement that is [ * ] to [ * ] for the [ * ] (it being understood that nothing
in this Amendment shall require either Party to [ * ] or [ * ]). If neither of (i) nor (ii) occurs during the Term, Astellas [ * ] pay the [ * ] of the [ * ] Milestone, [ * ] milestone amounts shall be payable for the [ * ] of a [ * ] for
the [ * ] or the [ * ] and Medivation shall in any event be permitted to retain the Three Million Dollars ($3,000,000.00) payable pursuant to Section 1.1 of this Amendment. Upon Astellas’s payment of the [ * ], [ * ] milestone amounts
under Section 9.4(a) shall be payable for the [ * ] of a [ * ] for [ * ] or the [ * ]. 
  

	2.	The [ * ] Milestone if Based on [ * ]. 

 2.1 Under Section 9.4(a) of the agreement, a milestone payment of [ * ] is payable within [ * ] after the [ * ] of [ * ] of [ * ] the [ * ] (the “[ * ] Milestone”). If such [
* ], and if, but only if, the [ * ] in such [ * ] the [ * ] of the [ * ] for the [ * ] is the [ * ], the parties will discuss in good faith and agree within [ * ] after such [ * ] whether [ * ] of the [ * ] should [ * ]. Such discussions and
agreement will be governed by Section 5 below. 
 2.2 If [ * ] of the [ * ] is so [ * ], such [ * ] shall be paid
within [ * ] following the earlier to occur of: (i) [ * ] of [ * ] for a [ * ] in the [ * ] with [ * ] the [ * ]; or (ii) the [ * ] in the [ * ] of [ * ] for the [ * ] in which the [ * ] to [ * ] of the [ * ] for the [ * ] is [ * ] the [ *
] (it being understood that nothing in this Amendment shall require either Party to [ * ] or [ * ]). If neither (i) nor (ii) occurs during the Term, Astellas [ * ] pay the [ * ] of the [ * ], [ * ] milestone amounts shall be payable for
the [ * ] of [ * ] in the [ * ] for the [ * ], and Medivation shall in any event be permitted to retain [ * ] the [ * ] payable on the 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2 

 
applicable Current Payment Date pursuant to Section 5.1 of this Amendment. Upon Astellas’s payment of the [ * ] of the [ * ], [ * ] milestone amounts under Section 9.4(a) shall be
payable for the [ * ] of [ * ] in the [ * ] of [ * ] for the [ * ]. 
  

	3.	The [ * ] Milestone if Based on [ * ]. 

 3.1 Under Section 9.4(a) of the agreement, a milestone payment of [ * ] is payable within [ * ] after the [ * ] of [ * ] in the [ * ] of [ * ] for the [ * ] (the “[ * ]
Milestone”). If such [ * ], and if, but only if, the [ * ] in such [ * ] the [ * ] of the [ * ] for the [ * ] is the [ * ], the parties will discuss in good faith and agree within [ * ] after such [ * ] whether [ * ] of the [ * ] should be
[ * ]. Such discussions and agreement will be governed by Section 5 below. 
 3.2 If [ * ] of the [ * ] is so [ * ],
such [ * ] shall be paid within [ * ] following the earlier to occur of: (i) [ * ] of [ * ] for [ * ] in the [ * ] with [ * ] the [ * ]; or (ii) the [ * ] in the [ * ] of a [ * ] for the [ * ] in which the [ * ] to [ * ] of the [ * ] for
the [ * ] is [ * ] the [ * ] (it being understood that nothing in this Amendment shall require either Party to [ * ] or [ * ]). If neither (i) nor (ii) occurs during the Term, Astellas [ * ] pay the [ * ] of the [ * ], [ * ] milestone
amounts shall be payable for the [ * ] of [ * ] in the [ * ] for [ * ], and Medivation shall in any event be permitted to retain [ * ] the [ * ] payable on the applicable Current Payment Date pursuant to Section 5.1 of this Amendment. Upon
Astellas’s payment of the [ * ] of the [ * ], [ * ] milestone amounts under Section 9.4(a) shall be payable for the [ * ] of [ * ] in the [ * ] of [ * ] for the [ * ]. 

 

	4.	The [ * ] Milestone if Based on [ * ]. 

 4.1 Under Section 9.4(a) of the agreement, a milestone payment of [ * ] is payable within [ * ] after the [ * ] of [ * ] in [ * ] of [ * ] for the [ * ] (the “[ * ]
Milestone”). If such [ * ], and if, but only if, the [ * ] in such [ * ] the [ * ] of the [ * ] for the [ * ] is the [ * ], the parties will discuss in good faith and agree within [ * ] after such [ * ] whether [ * ] of the [ * ] should be
[ * ]. Such discussions and agreement will be governed by Section 5 below. 
 4.2 If [ * ] of the [ * ] is so [ * ],
such [ * ] shall be paid within [ * ] following the earlier to occur of: (i) [ * ] of [ * ] for [ * ] in [ * ] with [ * ] the [ * ]; or (ii) the [ * ] in [ * ] of a [ * ] for the [ * ] in which the [ * ] to [ * ] of the [ * ] for the [ * ]
is [ * ] the [ * ] (it being understood that nothing in this Amendment shall require either Party to [ * ] or [ * ]). If neither (i) nor (ii) occurs during the Term, Astellas [ * ] pay the [ * ] of the [ * ], [ * ] milestone amounts shall
be payable for the [ * ] of [ * ] in [ * ] for the [ * ], and Medivation shall in any event be permitted to retain [ * ] the [ * ] payable on the applicable Current Payment Date pursuant to Section 5.1 of this Amendment. Upon Astellas’s
payment of the [ * ] of the [ * ], [ * ] milestone amounts under Section 9.4(a) shall be payable for the [ * ] of [ * ] in [ * ] of [ * ] for the [ * ]. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 3 

	5.	Good Faith Discussions and Agreement. 

 5.1 The guiding principle for good faith discussions to be held and agreement to be reached pursuant to Sections 2.1, 3.1 and/or 4.1 of this Amendment will be the [ * ], estimated reasonably
and in good faith by the parties, that assuming the applicable [ * ] is [ * ], the [ * ] will [ * ] (the “[ * ]”). Once the [ * ] is determined by the parties, [ * ] the applicable [ * ] the [ * ] shall be paid within [ * ]
following the end of the [ * ] good faith discussion period pursuant to Section 2.1, 3.1 and/or 4.1 (each such date a “Current Payment Date”), and the [ * ] of the [ * ] shall be [ * ] as provided in Sections 2.2, 3.2
and/or 4.2 of this Amendment, as applicable. The [ * ] will be determined [ * ] with respect to [ * ] and [ * ]. In determining the [ * ], the following rules will apply: 
 (a) If and after [ * ] or [ * ] for [ * ] is [ * ] the applicable [ * ] and the [ * ] is the [ * ] as the [ * ] the [ * ] of [ * ] in [ * ], then: 

(i) If the applicable [ * ] has [ * ] such [ * ] for [ * ] with [ * ] the [ * ], the presumption shall be that the applicable [ *
] shall be [ * ] on the applicable [ * ], and [ * ] shall be [ * ]; provided, however, that this presumption may be rebutted by Astellas based on any [ * ] the [ * ] and/or [ * ] of [ * ] and the [ * ] that can reasonably
be expected to have a [ * ] notwithstanding such [ * ]; and 
 (ii) If the applicable [ * ] has [ * ] such [ * ] for [ *
], or if the applicable [ * ] has [ * ] such [ * ] with [ * ] the [ * ], the presumption shall be that the applicable [ * ] shall be [ * ]; provided, however, that this presumption may be rebutted by Medivation based on
any [ * ] the [ * ] and/or [ * ] of [ * ] and the [ * ] that can reasonably be expected to have [ * ] notwithstanding such [ * ]. 
 (b) In all other circumstances, the [ * ] shall be based on the following factors, all as evaluated reasonably and in good faith by the Parties: 

(i) the [ * ] of the applicable [ * ] in [ * ]; 
 (ii) the overall [ * ] of the applicable [ * ] as assessed based upon [ * ]; 
 (iii) the similarity and difference between (i) the [ * ] and the [ * ] of the [ * ] and (ii) the [ * ] and [ * ] of [ * ]; and 

(iv) [ * ] and any other relevant factors, whether in existence as of the date of this Amendment or arising hereafter, that may
reasonably be expected to affect the [ * ]. 
  
 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 4 

 5.2 For avoidance of confusion: 

(a) In this Amendment, a [ * ] for [ * ] with [ * ] shall mean a [ * ], under any applicable laws and regulations, the [ * ] of [
* ] to any [ * ] (subject to [ * ] for [ * ] and [ * ] and the like), even if such [ * ] also [ * ] or [ * ] of [ * ] or [ * ]. 

(b) This Amendment shall not apply to any other milestones specified in Section 9.4(a) of the Collaboration Agreement,
including without limitation the milestones due upon [ * ] of [ * ] for the [ * ]. 
 (c) The [ * ] shall [ * ] to
account for [ * ] that the applicable [ * ] will be [ * ] by the applicable [ * ], but only for [ * ] that such [ * ], [ * ], will [ * ]. 
  

	6.	Miscellaneous. 

 6.1
Section 1 of this Amendment expressly supersedes the [ * ] under Section 9.4(a) and [ * ]. Section 9.4(a) of the Agreement is amended to reflect the provisions of Sections 2, 3, 4 and 5 of this Amendment. Except as specifically
amended herein, the Collaboration Agreement remains in full force and effect. Wherever the terms of this Amendment and the Collaboration Agreement conflict, the terms of this Amendment shall govern and control. 

6.2 This Amendment may be executed in counterparts, which together shall constitute one and the same instrument. 

IN WITNESS WHEREOF, the Parties have executed this Amendment by their duly authorized officers as of
the Amendment Effective Date. 
  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 5 

			
	 MEDIVATION, INC.

 
 By: /s/ C. Patrick Machado

 
 Name: C. Patrick Machado,

 
 Title: CFO / CBO
	  	 ASTELLAS PHARMA INC.

 
 By: /s/ Yoshihiko Hatanaka

 
 Name: Yoshihiko Hatanaka

 
 Title: Senior Corporate Executive, CFO

          and Chief Strategy Officer

		
	 MEDIVATION PROSTATE THERAPEUTICS, INC.

 
 By: /s/ C. Patrick Machado

 
 Name: C. Patrick Machado

 
 Title: CFO / CBO
	  	 ASTELLAS US LLC
  

By: /s/ Masao Yoshida
  
 Name: Masao Yoshida
  
 Title:
President and CEO

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]